版本:
中国

BRIEF-Intelgenx and Redhill Biopharma announce marketing approval of rizaport for migraines

April 13 Intelgenx Technologies Corp -

* Intelgenx and Redhill Biopharma announce marketing approval of rizaport(r) for migraines in Luxembourg

* Co, Redhill expect to re-submit rizaport 505(b)(2) new drug application to FDA in q3 of 2017

* Cos are continuing discussions with additional potential commercialization partners for rizaport in U.S. , Europe, other territories Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐